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Piecing together the puzzle: nanopore technology
in detection and quantification of cancer
biomarkers
Trang Vu,a Shanna-Leigh Davidson,a Julia Borgesi,a Mowla Maksudul,a
Tae-Joon Jeonb and Jiwook Shim *a
Cancer is the result of a multistep process, including various genetic and epigenetic alterations, such as
structural variants, transcriptional factors, telomere length, DNA methylation, histone–DNA modification,
and aberrant expression of miRNAs. These changes cause gene defects in one of two ways: (1) gain in
function which shows enhanced expression or activation of oncogenes, or (2) loss of function which
shows repression or inactivation of tumor-suppressor genes. However, most conventional methods for
screening and diagnosing cancers require highly trained experts, intensive labor, large counter space
(footprint) and extensive capital costs. Consequently, current approaches for cancer detection are still
considered highly novel and are not yet practically applicable for clinical usage. Nanopore-based
technology has grown rapidly in recent years, which have seen the wide application of biosensing
research to a number of life sciences. In this review paper, we present a comprehensive outline of
various genetic and epigenetic causal factors of cancer at the molecular level, as well as the use of
nanopore technology in the detection and study of those specific factors. With the ability to detect both
genetic and epigenetic alterations, nanopore technology would offer a cost-efficient, labor-free and
highly practical approach to diagnosing pre-cancerous stages and early-staged tumors in both clinical
and laboratory settings.
1. What is nanopore (NP) technology?
Formal denitions of NP-based technologies typically feature
devices that contain a nanometer-scale pore embedded in a thin
membrane. Originating from the Coulter counter and ion
channels, NP-based devices can detect various charged
biomolecules that are slightly smaller than the diameter of the
pore. In the NP-based analysis, a biological or a solid-state
membrane separates the experimental chamber into two
compartments, referred to as the cis and trans sides, to which
the cathode and anode are attached, respectively. Negatively
charged biomolecules, such as DNA, are then introduced into
the cis side of the chamber. Under the electrophoretic force
exerted by the external voltage, the biomolecule transports
through the NP to the trans chamber. As the molecule moves
through the NP, it interrupts the current signal, causing ionic
current blockages. Physical and chemical properties of the tar-
geted molecule can be analyzed using the amplitude and
duration of current blockages through the NP (Fig. 1).1,2
Both biological and solid-state NPs, which can be obtained
or fabricated in numerous ways,3–8 offer a wide range of
biomolecule detection. Biological NP is secreted from different
bacteria, in which the two most popular types come from a-
Hemolysin and MspA porin. These biological NPs are then
usually inserted into different biological substrates, such as
a phospholipid bilayer, liposomes, or polymer lms. Biological
membranes are structurally well-dened and easily reproduc-
ible. Biological NP is mostly used for the detection of single-
stranded DNA (ssDNA), microRNA (miRNA), and disease diag-
nostics.2 Most solid-state NPs are fabricated in membranes
made of silicon oxide (SiO), silicon nitride (SiNx), hafnium oxide
(HfO2), graphene, aluminum oxide (Al2O3) and hybrid mate-
rials.9–11 With controllable pore size and membrane thickness,
solid-state NPs have been benecial for use in RNA sequencing,
single-stranded and double-stranded DNA sequencing, DNA–
protein complex detection, and other biomolecule detection.
2. Key concepts of cancer
development
The development of a malignant cancerous tumor frequently
results from a multistep process, rather than just a single
genetic change.12 This multistep process originates from
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various genetic and epigenetic modications. Genetic modi-
cations include structural variants, aberrant transcription
factors activity, and telomere oxidative damage. The epigenetic
modications include DNAmethylation, histone modications,
and aberrant expression of miRNAs. Both genetic and epige-
netic alterations exert their pathological effects by causing
defects in genes in one of two ways: (1) an enhanced expression
or activation of oncogenes – gain in function- and/or (2)
repression or inactivation of tumor-suppressor genes – loss of
function.13 Several methods have been used in research for
detecting various cancer-causing factors and different tech-
niques are applied depending on the particular type of cancer.
3. Toward personalized genomic
medicines for cancer studies
Using the concept of massively parallel sequencing, the devel-
opment of high-throughput next-generation sequencing (NGS)
devices, particularly Illumina, Complete Genomics, and Roche
Applied Science 454 among many others, have revolutionized
personalized genomic medicines. In fact, for the rst time,
several clinical samples of patients were obtained and analyzed
with NGS, providing an insight to the high complexity of
diseases such as cancer.14–21 While providing high-throughput
and high accuracy reads, NGS still requires multiple process-
ing steps and le formats for their outputs (e.g. FASTQ, BAM,
SAM and VCF).22,23 The high volumes of data generated by NGS
make managing and storing results one of the major challenges
for clinical laboratories.24 Furthermore, NGS technologies
employ several enrichment, amplication, and labeling steps,
such as polymerase chain reaction (PCR) and bisulte conver-
sions, causing the performance to be time and cost intensive, as
well as increasing the possibility of false positive results.25 Due
to the need of a label-free, high throughput system, there has
been a growing interest toward using third- and fourth-
generation sequencing, specically NP technologies, in cancer
prevention and detection in the past decades.
Since its development and publication in 1996, the NP has
become an emergent and powerful technology for a direct and
inexpensive method for DNA sequencing, biosensing, and
detecting biological or chemical modications on single mole-
cules, as well as the kinetics of DNA and protein folding. NP
technology offers many advantages that NGS devices are inca-
pable of. For example, NP has demonstrated the ability to detect
CpGs methylation (one of the earliest epigenetic biomarkers in
cancer hallmarks) without the need of PCR amplication and
bisulte conversion.26,27 Thus, NP technology strives to be
a potential genomic tool that is label-free, has a high
throughput, a small sample volume requirement, exible run-
time, and minimal footprint.2 However, despite the past twenty
years of signicant progress in single molecular sequencing and
analysis, NP technologies have not yet been translated into even
distantly comparable advances in clinical settings. There are
two general, synergistic goals that have been striven for to
increase the efficacy of single molecule analysis using NP: to
decrease the translocation time of biomolecules through the
pore and to increase the base-calling accuracy. An ideal single
molecule analysis system would be highly accurate, have a high
throughput, and be sensitive to both genetic and epigenetic
changes of the cancer genome. Many previous articles have
extensively discussed the potential and development of NP
technology, especially in DNA sequencing.2,3,28–32 However, to
the best of our knowledge, an article focusing solely on the
application of NP technology in the early detection of various
types of cancer biomarkers and causal factors has yet to be
published. We believe this review will contribute to the further
understanding of the potentials and challenges of applying NP
technology in cancer research. Herein, we provide a brief over-
view of the six main cancer-causing factors, along with methods
conventionally used in detecting cancer at the molecular level.
We then focus on reviewing NP technology with a focus on its
development as a method for specic molecular detection, as
well as its future potential and challenges in the clinical
domain. All studies presented here are not intended to form an
exhaustive list, but rather, to illustrate the totality of our major
achievements and challenges of applying NP technology in early
cancer detection.
4. Detection of genetic modifications
using nanopores
4.1 Structural variants
Structural variants (SVs) are one of the rst recognized causal
factors of cancer. A structural variant is a form of somatic DNA
mutation, whereby the SV promotes the development and
progression of cancer while contributing to all the important
hallmarks of the instability in cancer genomes.33 The four main
types of SVs are large deletions, amplications, inversions and
translocations of nucleotides within a DNA sequence. They are
oen responsible for the creation of fusion genes, copy number,
Fig. 1 Schematic view of the NP-based experimental setup. The two
chambers (cis and trans) are separated by a membrane, which is
usually either biological or solid-state. A nanopore, which was
embedded/fabricated into the membrane, acts as the single channel
connecting the two chambers. DNA is added to the cis side. Under the
electrophoretic force exerted by applied voltage, DNA strands trans-
locate through the NP to the trans chamber, creating characteristic
current blockages.2


























































































and other regulatory changes that lead to activation or over-
expression of oncogenes, as well as inactivation of tumor
suppressor genes.34–38 In many cases, different SVs occur
simultaneously in a specic pathway that amplies their genetic
effects on cell instability. For example, with head and neck
cancers, it was found that when the deletion of CDKN2A and
amplication of CCND1 happen together, there is a higher risk
of recurrence, metastasis, and death rather than when either
genetic alteration occurs alone.37,39
SVs are important indicators of human cancers.33,41–43
Complex SVs have been found to cause approximately half of
nucleotide deletions in pancreatic ductal adenocarcinoma
(PDAC).44–46 Furthermore, CDKN2A/p16 and SMAD4/DPaazC4
have been identied as two of the most common deleted tumor
suppressor genes. The ability to detect these mutations is crit-
ically important to the healthcare industry, allowing the moni-
toring of cancer patients for early detection of possible
relapse.33,44–47 In mammalian cells with highly repetitive
genomes, studies of SVs frequently use a resequencing
approach, in which the read from the target genome is inde-
pendently aligned from the reference genome to search for
SVs.48 In general, besides specicity and sensitivity, when
detecting SVs, a method's quality is further judged by its ability
to accurately predict breakpoint locations, the size of variants,
and changes in copy count.33,49
Norris et al. demonstrated the value of detecting long SVs
using Oxford MinION™, to detect a series of well-characterized
SVs, including large deletions, inversions, and translocations
that inactivate the CDKN2A/p16 and SMAD4/DPC4 tumor
suppressor genes in pancreatic cancer.33 Using Oxford Nano-
pore barcodes, the Norris et al. produced libraries for all 12 PCR
amplicons in one run, yielding reads with PHRED scores of
10.9–11.50. PHRED, invented back in 1998 by Ewing and Green,
was originally a base-calling program for automated sequencer
traces. In later research, the term “PHRED score” has been used
for the determination of quality and accuracy between
consensus sequences. The higher the PHRED score, the higher
the accuracy. For example, a PHRED score of 10 stands for
a 90% base call accuracy, and a PHRED score of 20 is correlated
with 99% base call accuracy.50 For this specic study, the
readings were averaged at 640 bps long with a PHRED score of
11.50. It was also found that these reads are consistent for the
entire bps length. The amplicons mapped with an overall
percentage of 99.6% for regions of hg19, while 79% of aligned
reads accurately matched to bases. Notably, the representation
of amplicons does not change accuracy based on the complexity
of the sequence. Additionally, the researchers wanted to test
their method with low frequency SVs. In a 1 : 100 dilutions, the
run produced 4058 2D reads from 270 of 512 channels. The
average read length was 650 bps and had a PHRED score of 10.9.
Overall, the researchers proved their methods can be conducted
in a timely manner. For the two sequences (CDKN2A/p16 and
SMAD4/DPC4) in this study, it took 15 minutes and 33 minutes
respectively, to generate 450 reads.33 In comparison, 2nd
Fig. 2 Detecting structural variants with nanopore. (A–D) Schematic of the Oxford MinION Nanopore Library Prep workflow. Oxford Nanopore
barcodes were pooled into amplicons by PCR. After NEB End Repair and dA-tailing modules, hairpin and leader adapters were ligated on, each
containing a motor protein (orange). Then, tether attachment allowed DNAmolecules to attach to the membrane of MinION flowcell. Within the
flowcell, molecules, each with attached motor proteins, were pulled through a nanopore, producing 2D consensus read. (E) Size comparison
between an Oxford MinION and a quarter coin.33


























































































generation sequencers could generate millions of reads simul-
taneously, but it would take hours to days to complete. The
experiment indicated the ability of NPs to serve as a reliable and
efficient method of sequencing, allowing rapid detection of
tumor-associated structural variants. The two limitations of
MinION™, as noted by the researchers, were (1) a relatively high
mismatch and index error rate and (2) a limited yield (on the
scale of Mb or Gb) (Fig. 2).
Comparing to conventional genome-based methods, such as
uorescence in situ hybridization (FISH), ber-FISH, array
comparative genomic hybridization (aCGH) and paired-end
mapping (PEM), which have a read length of approximately
35–400 base pairs (bps),40,49 NP allows a muchmore exible read
lengths (of a few bps to kbps). However, the average PHRED
score of reads generated by MinION is still relatively low
compared to other sequencers (e.g. Illumina, 454, Ion Torrent,
and PacBio). At the moment, Illumina is the most popular DNA
sequencer on the market. Still, depending on the equipment
model and sample size, sequencing using Illumina can take
from 3–12 days to complete. Additionally, the current market
price of Illumina ranges from $50 000 (MiniSeq) to over $6M
(Illumina HiSeq X Five), costing tremendously more than the
NP-based sequencers.
4.2 Transcriptional factors
The second most well-known causal factor of cancer is aberrant
activity of transcription factors (TFs), which are oen members
of multigene families with common structural domains.12 TFs
are the main regulators of gene expression and signaling
pathways in all biological systems and bind to a specic
sequence of DNA to promote or inhibit gene expression. In cells,
a major portion of oncogenes and tumor-suppressor genes are
encoded by TFs.13,51 Aberrant TF activity can occur due to
changes in expression, protein stability, protein–protein inter-
actions, post-translational modications, and numerous other
mechanisms.52 In a healthy cell, upstream transcriptional
regulators highly regulate all genes with similar functions.
However, changes in TF activity leads to deregulation of genes
involved in promoting cancer cell proliferation, survival, and
inducing angiogenesis and metastasis of tumors.13,51 For
example, nuclear TFs, the signal transducer and activator of
transcription, has been linked to various human cancer cell
lines and primary tumors, including leukemia and lymphoma,
as well as breast, lung, pancreas, and prostate cancers.34–38,53–57
Various direct and indirect techniques have been used to
characterize TFs, along with other sequence-specic DNA
binding proteins, including electrophoresis, electrophoretic
mobility shi assay, nuclear magnetic resonance, X-ray crys-
tallography, atomic force microscopy, optical tweezers, and
direct uorescent visualization, among others.58–63 However,
most of these methods require some combination of chemical
cross-linking between TFs and DNA, modication or tagging of
the TF and DNA, and amplication assays. Furthermore, due to
the complicated requirements, these methods would lack the
ability to resolve ne details of the TF and DNA complex (i.e.
partial versus full binding of the TF domains to DNA).63 The
specic mechanism of TFs binding to DNA sequences is still
under invasive study and is a major area of interest in molecular
biology.63,64
Squires et al. used solid-state NPs as biosensors for the
characterization of DNA, RNA, and proteins. With the use of an
electric eld, the researchers could guide the polymers through
a NP and identify individual molecules. The current-blockage
patterns generated during translocation of charged molecules
provides an abundance of information about TF local proper-
ties, as well as TF–DNA interactions.63 As previously noted, the
regulation of TFs has not been well investigated, hence the use
of solid-state NPs could be a novel technique in describing these
molecular interactions. As proof of technique, the Squires et al.
has shown that their NPs can distinguish between specic and
nonspecic binding of TF, by analyzing the ion current of the
canonical zinc-nger DNA-binding domain of early growth
response 1 (zif268). Characterization of the zif268 was accom-
plished using the distinct blockage patterns of the current
within the nanopore.65 Through analyzing the data, the
researchers found that there are three main types of blockages,
existing mostly in ve distinct patterns rather than randomly.
These patterns have a direct correlation to preexisting data.
Hence, the NP presents great potential in characterizing DNA
complexes because of its ability to detect complex structures
and protein conformations, with the possibility of removing TFs
as needed. Squires et al. note that their NP sensor can identify
small TFs in DNA as well as distinguish between specic and
nonspecic binding. This research technique allows
information-gathering availability with respect to TF–DNA
interactions (Fig. 3).
4.3 Telomeres
On average, telomeres are shortened by 19 bps per year due to
aging, oxidation, stress, mitotic activity of tissues, and life-
style.66–69 When shortened to a critical length, telomeres lose
their ability to protect the DNA chromosomes70 and restrict the
proliferation of normal somatic cells.69 This leads to chromo-
somal fusion and degradation.71,72 In contrast, approximately
Fig. 3 Distinguishing between specific and non-specific binding of
TF—DNA with solid-state nanopore. Translocation event traces and
proposed mechanisms for (A) specific binding, and (B) non-specific
binding of TF to DNA.63


























































































85% of human cancer cells can achieve an “immortality” status
by maintaining and elongating telomeres via the de novo
synthesis of telomeric DNA.71 A study was conducted on 47 102
individuals from the general population, where these individ-
uals were followed for up to 20 years to nd out the relationship
between telomere length and cancer. Although short telomere
length is not an indication of cancer,69 it was observed that
cancer patients with shorter telomere length had increased risk
of early death. This result was observed in patients with lung
and esophagus cancer, malignant melanoma, and leukemia.69
Even though it has been years since the rst research, the
kinetics of telomeres in cancer cells remains elusive. At present,
measuring the length of telomeres and observing the kinetics of
folding are still challenging, as there is no gold-standard tech-
nique.73 In order to fully understand the role of telomeres in
cancer prediction or therapy, it is essential to understand the
kinetics of telomere folding and other conformational changes
as a response to different living and environmental conditions.
Work is currently underway to apply NP sensor in tracking
the telomeric DNA G-quadruplex folding/unfolding. Several
research groups have used biological NP to capture some or all
four folded-structures of G-quadruplex, including hybrid
(hybrid-1 and hybrid-2), basket, and propeller structures.10,74–76
Findings from these studies reported that even though the four
G-quadruplex structures all folded from the same DNA
sequence, they produced very different electrical signatures.76
This was attributed to the overall shape and volume of each
secondary structure. It was observed that both hybrid-1, -2, and
basket forms had a diameter of 2.7 nm and 2.4 nm, respectively.
Since the cis opening of the a-hemolysin pore has a diameter of
3.0 nm, these three folds can enter the large vestibule. However,
the propeller fold, with a disk-shaped structure and diameter of
4.0 nm, exceeds the diameter of the NP cis opening and was
unable to enter the vestibule.77
Another inventive solution to capture and unravel G-
quadruplexes is to employ a 25-mer poly-20deoxyadenosine tail
(d25A-tail) on the 50 end of the telomeric DNA. Applying this
method, the Burrows group reported the analysis of various
folding motifs of the telomere sequence, with and without the 50-
d25A-tails.76 Among the four loop topologies, only the basket fold
was able to translocate through the NPwithout the addition of the
homopolymer tail to the 50 end. For the G-quadruplex to move
through the NP, it needs to unravel to a singular strand which
would be able to translocate through the narrow b-barrel, and the
remaining G-triplex has to roll within the vestibule. This is likely
a favorable process for the basket fold because of its nearly
spherical shape.78 Even though the volume of the vestibule is large
enough to accommodate all four G-quadruplexes within its cavity,
the narrow entrance of the vestibule prevented the propeller fold
from entering the NP. However, with the addition of the 50 tail, the
propeller fold was able to circumvent the problem of entering the
cavity, and yet still had a very fast translocation signature. This is
attributed to the fact that the propeller fold was able to roll outside
of the vestibule while an electric force was applied to the dA25-tail
as it threaded through the ion channel, without having any
molecular interactions or steric hindrance that would have been
experienced on the interior of the vestibule.76
In the light of those previous studies, for the rst time, the
unfolding kinetics of human i-motifs were studied using the a-
hemolysin NP. Under acidic conditions, cytosine (C)-rich DNA
sequences can adopt i-motif folds, since the hemi-protonation
of C-rich strands allow C+$C base pairs to form.79 The Ding
et al. conducted experiments on the human i-motif sequence at
a constant ionic strength, but various pH (5.0–7.2). Since the
dimension of an i-motif (2.0 nm  2.0 nm) is smaller than cis
opening (3.0 nm) of the a-hemolysin pore, it can enter the
pore without unfolding and be captured in the nanocavity.79
Hence, a d25A tail was attached to the sequence, in order to
increase the unfolding rate of i-motif. Upon the attachment of
d25A, it was observed that at pH 5.0, the folded structure
entered the a-HL pore, yielding characteristic current patterns.
However, when the pH was at 6.8 and 7.2 (higher than the
transition pH 6.15), the percentage of strands still folded was
4% and 2%, respectively. Furthermore, the force applied in this
study was analogous to the forces exerted on genomic DNA by
RNA polymerases II (5–20 pN) and DNA helicase (6–16 pN).79
Hence, these studies strive to show the potential of a-hemolysin
as part of biosensor development, aiding in our knowledge of
the lifetimes of i-motifs of telomere sequences, and their bio-
logically relevant structures, which can be used as drug delivery
targets for cancer treatments.80
These ndings are steps toward a better understanding of
the folding and unfolding mechanisms of the telomere. When
pre-detecting different cancer types, conventional methods,
such as FISH, Southern blot, and quantitative-PCR, require
complicated meta-analyses, chemical-crosslinking and inten-
sive preparation; hence the results are inconsistent.69,81–83
Whereas NP analysis, lacking all those complications, allows
a better understanding of the kinetics and mechanisms, aiding
in the analysis of how different oxidation, stress and factors
affect the length of telomeres, as well as the correlation between
cancer development and telomere immortality (Fig. 4).
5. Detection of epigenetic
modifications using nanopores
5.1 DNA methylation
Hyper- and hypomethylation of CpGs. In humans, methyla-
tion of DNA is an epigenetic modication that transfers
a methyl group from S-adenosyl-methionine to cytosine resi-
dues, forming 5-methylcytosine (5-mC). In mammalian cells,
methylation of CpGs can directly or indirectly repress gene
expression. For example, hypermethylation of CpG islands in
the promoter region can directly lead to transcriptional
silencing of tumor-suppressor genes. On the other hand,
methylated CpGs can indirectly interfere with transcription to
prevent the binding of basal transcriptional machinery or
ubiquitous TFs. This process contributes to all of the typical
hallmarks of a cancer cell originated from tumor-suppressor
inactivation.84 With aging, cell deregulation provides mutation
accumulation and epigenetic alterations (i.e. aberrant methyl-
ation in DNA) the chance to build up, causing proliferative
advantages and genomic instability. Aberrant DNAmethylation,


























































































including loss of methylation (hypomethylation) and gain of
methylation (hypermethylation), has been classied as
a common causal factor of many cancers.85–89 For instance,
hypermethylation is linked to various types of cancers,
including lung, prostate, breast and colon cancers,90–93 while
hypomethylation of CpGs has been reported to be associated
with kidney, liver, pancreas, lung, cervix, stomach and uterus
cancers.94–99 Hence, detecting aberrant DNA methylation can
have an important role in cancer treatment and precancerous
detection.26,100
The overall level of 5-methylcystosine contained in the cell
sample can be quantied using high-performance liquid chro-
matography (HPLC), high-performance capillary electropho-
resis (HPCE), bisulte sequencing, methylation-specic PCR,
among many others.102–108 However, these methods have certain
drawbacks. For example, although HPLC and HPCE can accu-
rately quantify the total amount of methylated CpGs, they have
incomplete restriction enzyme cutting, offer limited region of
study, require substantial amounts of high molecular weight
DNA, and are labor intensive. Similarly, with PCR-based
methods, only the methylation status of CpG sites that are
complementary to the primers can be interrogated. Thus, the
predominant methylation patterns in the sample may not
necessarily reect the actual results (false positive results).
With NP analysis, current methods used in the detection of
aberrant CpGs methylation usually employ either a methylation
specic labeler, or an electro-optical tagging.26,27,109 The rst
method, as proposed by Shim et al., employs an engineered
methyl-CpG-binding domain protein (i.e. MBD1x or Kaiso Zinc
Finger proteins) as a selective labeler to detect and quantify
hypermethylated CpG sites in double-stranded DNA
(dsDNA).26,109 As the DNA translocated through the NP, the
presence of 5-mC$labeler complexes caused a signature current
blockage, allowing the detection and coarse quantication of 5-
mC sites on a single molecule.109 Indeed, this method set an
initial application in screening for the presence of hyper- and
hypomethylated DNA. Moreover, Shim et al. pointed out that
with the versatile binding affinity of KZF to various methylation
patterns, the studied assay can allow various patterns to be
screened.26 Since NP analysis requires low volumes of DNA for
testing, the technique will be more applicable and practical for
clinical use. Without the need of DNA replication and ampli-
cation, detecting CpG methylation using NPs requires much
less labor in comparison to other conventional methods.
The second method, as mentioned before, uses an electro-
optical solid-state NP to detect and quantify hypomethylation
in DNA.27 In this approach, enzyme DNAMTases was assisted by
small molecular weight synthetic cofactors to catalyze a one-
Fig. 4 Capturing unfolding process of the four G-quadruplex structures with biological nanopore. (A) Schematic of the a-hemolysin NP, with the
cis opening of 3.0 nm, constriction of 1.4 nm, and trans opening of 2.0 nm. (B) Folding structures and dimensions of G-quadruplex confor-
mations: hybrid-1, hybrid-2, basket, and propeller. (C) G-Quadruplex fold entered and unfold inside the nanocavity of a-hemolysin NP, causing
two distinct levels of blockade. (D) Except the propeller fold, all other G-quadruplex can enter the cis opening of a-hemolysin NP without
unfolding, but cannot pass through the pore constriction.65 (E) Models of the three conformations with the additional 50-dA25 tail unraveling
through a-hemolysin pore. Both hybrid and basket folds were able to enter the cis opening of the a-hemolysin pore, thus unraveled inside the
pore nanocavity. On the other hand, propeller fold, because of its size, could not enter the NP. This conformation unraveled its structure outside
of the pore, using the help of the 50-dA25 additional tail.65


























































































step enzymatic reaction. This enzyme–cofactor complex was
directly conjugated onto uorescent probes and attached to the
unmethylated CpG sites. The Meller group was able to detect
and differentiate between fully methylated, partially methylated
and unmethylated dsDNA, using ultrasensitive electro-optical
NP sensing as the tool for single-uorophore multicolor quan-
tication. Unlike MBPs, DNA MTase only labeled unmethylated
CpG sites of the target DNA. This allowed the direct targeting of
hypomethylated CpG sites in the genome (i.e. promoter regions
of oncogenes). Furthermore, this electro-optical solid-state NP
showed a high potential for employing multiple DNA MTases
and other epigenetic biomarkers. With the aid of those
biomarkers, orthogonal labeling/sensing of 5-mC can be ach-
ieved in the future.27 Further research must be done in order to
develop a calibrated scale to count the number of unmethylated
CpGs in the target sequence.
Other variants of CpGs methylation: mC, hmC, caC, and fC.
Recent discoveries of three other variants of cytosine made the
study of DNA methylation even more complex. The family of
Ten-Eleven Translocation (TET) proteins have been shown to
oxidize methylcytosine (mC) into hydroxymethylcytosine (hmC)
and further oxidize hmC into formylcytosine (fC) and carbox-
ylcytosine (caC).110–113 5-hmC normally exists at a high level in
self-renewing and pluripotent stem cells.110,114 Both mc and
hmC inuence mammalian embryonic stem cell mainte-
nance,115,116 angiogenesis,117 and development.118 Thus, hmC is
a promising molecular biomarker with predictive and prog-
nostic value.119 As for fC and caC, there is still very little research
being done. Because the topic has just recently been discovered,
we currently lack a robust method to distinguish between these
ve chemical modications of cytosine. Even distinguishing
betweenmC and hmC is a challenge for available methods.116,120
The presence of bulk 5-methylcytosine (5-mC) and 5-
hydroxymethylcytosine (5-hmC) on ss- and dsDNA has been
successfully detected and distinguished using both solid-state
and biological NPs.121–123 For instance, the Drndic group
proposed a method using solid-state NP to discriminate two
different structures that translocated through the pore (5-mC
and 5-hmC). Upon the addition of 3 kbp dsDNA, a sequence of
current blockage was generated, in which the magnitude of
each spike was related to the excluded volume of biopolymer
that occupies the pore. From the differences in DImax values,
Wanunu et al. was able to discriminate between 5-mC and 5-
hmC. Shorter end-to-end distance of the more polar 5-hmC
indicated an increased exibility in 5-hmC comparing to cyto-
sine and 5-mC. Moreover, it was shown that different propor-
tions of 5-hmC in DNA fragment containing cytosine and 5-mC
can be quantied using ionic current signal.121 The second
device used in the detection of CpG methylation variants
employed both the wild-type phi29 DNA polymerase (phi29
DNAP) and MspA in the same assay.122,123 With this unique
approach, the Wescoe et al. reported a direction detection of all
ve cytosine variants (C, mC, hmC, fC and caC). In this single-
molecule tool, a phi29DNA polymerase drew ssDNA through the
pore in single-nucleotide steps and the ion current through the
pore was recorded.122 Overall, the single-pass call ranged from
approximately 91.6% to 98.3% depending on neighboring
nucleotides.122,123 Since the knowledge of the ve cytosine vari-
ants, especially fC and caC, is still very limited, the possibility of
these variants having an impact on genome-wide demethylation
or other modications in cancer cells should not be eliminated.
These studies have shown NP analysis potential as a robust
and efficient tool for the study of DNA methylation. The tech-
nique can directly detect CpG methylation without the need for
DNA amplication or complicated preparation processes. Due
to its special characteristics, methylation of CpG is usually
erased during replication and amplication. Bisulte conver-
sion, for example, requires large amplication, leading to false
positive results. Hence, NP analysis could be a more practical
and reliable method to screen and detect aberrant DNA meth-
ylation in cancer patients. However, in order to apply NP tech-
nology to clinical trials and testing, a genome-wide mapping of
CpG methylation needs to be developed with a higher base-call
accuracy (Fig. 5).
5.2 Histone–DNA modications
Results from several studies have indicated that aberrant DNA–
methylations are also linked to the presence of aberrant histone
modications.101,124–127 Histones are the gene activity's dynamic
regulators. They go through several post-translational modi-
cations, such as acetylation, methylation, phosphorylation,
ubiquitylation and others. Specically, methylation and acety-
lation of lysine residues on the nucleosomal core histones play
an essential role in gene expression and chromatin structure
regulation.128 In normal cells, histones in DNA sequences are
hypoacetylated and hypermethylated. The two key regulators of
histone modications are histone deacetylases and histone
methyltransferases (MTases), which are associated with methyl-
binding proteins (MBPs) and MTases.128–130 However, global
alterations of histone modication patterns can interrupt
normal gene expression, thus the genome's structure and
integrity.131 Structurally, histone can assemble into octamers,
where a strand of 146 bps long DNA then wraps around to create
a nucleosome. Acetylation or deacetylation of the lysine residue
on nucleosomes can promote or suppress DNA replication
accordingly. Accumulation of histones and nucleosomes in
a cell has also been shown to be the early markers of cell
death.132,133 Although it is well known that epigenetic modi-
cations of histones can affect different nucleosome structures,
the mechanism(s) of action is still unknown.134–136
Several studies have been conducted on the translocation or
unravelling of a nucleosome and its subunit structure through
NP.136,138,139 Generally, it was found that DNA–histone complexes
lead to higher applied voltage required and overall longer time
periods to translocate through the NP, most likely due to either:
(1) the bulky disk shape nucleosome experienced a higher drag
force comparing to a bare dsDNA, (2) the positively charged
histone core lowered the total net charge density of nucleo-
somes, causing the translocation speed in electrophoresis to
reduce, and (3) the unwinding process of histone–DNA
complex.136,140
As mentioned earlier, epigenetic modications have been
known to affect the structural integrity and stability of


























































































nucleosomes. Given this fact, it was hypothesized that methyl-
ation of CpGs on dsDNA would affect the way nucleosomes fold
and/or unravel. To test this hypothesis, the Langecker et al.
investigated the inuence of DNAmethylation on the stability of
unlabeled mononucleosomes.139 Similar to the results reported
in other studies, under the electrophoretic force, the nucleo-
somal DNA tail entered the pore and gradually unraveled under
increasing voltage, which was much higher in comparison with
free DNA capture.141 This experiment was repeated on nucleo-
somes with and without methylated DNA sequences, yielding
that methylation of CpGs did not affect the nucleosome
assembly, stability, or unraveling trajectories. This nding
suggested that histone modications (i.e. acetylation and
phosphorylation) play a much more dominant role in nucleo-
somal maintenance than DNAmethylation. The conrmation of
methylation-independent nucleosome stability indicated other
possible mechanisms by which DNA methylation alters gene
expression, for example, modulating the binding of transcrip-
tion activators/repressor.139
The NP-based studies outlined herein lay the groundwork for
understanding and predicting the inuence of different histone
core modications on the nucleosome structure,139 in which our
knowledge is still quite limited. Unlike conventional methods
(i.e., single-gene chromatin immunoprecipitation (ChIP), ChIP
with a DNA array (ChIP-on-chip),142,143 HPLC, HPCE, and many
others), NP devices is more versatile, because they do not rely
heavily on the quality of the polyclonal antibodies or antibodies
that are available.101 Although the study here indicated that DNA
methylation does not affect the nucleosome assemble, further
studies need to be done in order to conrm the role of DNA
Fig. 5 Distinguishing variants of cytosine with biological and solid state nanopores. (A) Chemical structures of cytosine and its variants. First row:
mC (left) and fC (right). Second row: cytosine. Third row: hmC (left) and caC (right).122 (B) Schematic of the Phi 29 DNAP–MspA complex. MspA
pore constriction is shorter and narrower compared to a-hemolysin (as shown in the top), allowing short subtle structural changes to be
distinguished. (C) A typical trace of DNA translocation through the Phi 29 DNAP – MspA complex.121 (D) Detection of DNA methylation with
methyl binding proteins (MBP) using solid state nanopore. MBPs bind to methylated CpGs on DNA, allow the detection and differentiation
between unmethylated, hypermethylated and locally methylated DNAs. (E) Detection of DNA methylation with optical-tagging using solid-state
nanopore.27


























































































methylation in other processes (i.e. regulating transcription
activators/repressors binding, or gene expressions), as well as
the relationship between acetylation and phosphorylation on
nucleosome assembly, and chromatin stability.
5.3 MicroRNA
MiRNAs are small endogenous biomolecules that are in length
of 18–22 bps. They play an important role in embryonic differ-
entiation, hematopoiesis, cardiac hypertrophy and numerous
cancer-related processes, including proliferation, apoptosis,
differentiation, migration and metabolism.144,145 Since a single
miRNA can target up to hundreds of mRNAs,137 an aberrant
miRNA expression may affect several transcripts and cancer-
related signaling pathways. In cancer cells, because of the
genetic diversity of tumors and cancer cell lines, an individual
miRNA can be up-regulated in one type of cancer and down-
regulated in another.137 Overall, miRNAs function depends on
their targets within the specic tissue.12 Usually, the up-
regulated miRNAs function as oncogenes by down-regulating
tumor-suppressor genes, while the down-regulated miRNAs
function as tumor-suppressor genes by down-regulating
oncogenes.
Detection of miRNAs faces several challenges, mainly due to
the shortness of miRNAs. Some quantitative methods have been
applied to miRNA detection with enhanced sensitivity and/or
selectivity, including quantitative reverse transcription real-
time polymerase chain reaction (qRT-PCR) assays, micro-
arrays, colorimetry, bioluminescence, enzyme turnover, elec-
trochemistry, molecular beacons, deep sequencing and single-
molecule uorescence.146–149 Unfortunately, these techniques
incur DNA amplication errors, unavailable internal controls,
and cross-hybridization. Also, the short sequence of miRNAs
makes the designing of probes and primers even more
challenging.146,148
MiRNAs have been investigated as potential molecular
biomarkers, because their expression levels are associated with
various diseases.150 For instance, each year, lung cancer causes
approximately 1.2 million deaths worldwide.151 Since there is no
effective screening procedure available, more than 70% of lung
cancer patients were diagnosed with less than a 15% chance of
a 5 year survival rate.151 More than 100 types of miRNAs have
been identied to deregulate lung cancer progression.150
Noticeably, high levels of miR155 and low levels of let-7a-2 have
been associated with a signicantly poor prognosis and shorter
Fig. 6 Detection of a miR-155 using using solid-state and biological a-hemolysin nanopores. (A) Schematic of miRNA detection with viral
proteins for probe-specific miRNA, using solid-state nanopore. Protein from Carnation Italian ringspot virus was used to enrich miRNA form
background fluid. (B) Detection of probe-specificmiRNA using alpha-hemolysin biological nanopore. MiRNA-155 (shown in red) was attached to
a DNA P155 probe (shown in green). (C) At 8.0 pH and 100 mV, translocation of the miRNA-155$P155 resulted in various current blockage
patterns. (C) A typical current blockade with three characteristic blocking levels, representing the mechanism of miRNA-155$P155 complex
dissociation and translocation through the pore (as shown in the right-hand side).154


























































































survival times in lung cancer patients.152,153 Many research
groups have used biological and solid-state NPs for the detec-
tion of miRNAs in different tissues. For example, the solid-state
NP was used for rapid detection of probe-specic miRNAs
(miRNA-122a and miRNA-153).154 Specically, for every 1 fmol of
miRNA duplex per mL solution, the capture rate was 1 molecule
per second. In this study, the p19 protein from the Carnation
Italian ringspot virus was used to enrich miRNA-122a and
miRNA-153. Since miRNA concentrations were 1% relative to
other cellular RNAs, to detect a specic miRNA using a NP
sequence, an enrichment step was required.154 P19 binds 21–23
bps dsRNA in a size-dependent, but sequence-independent
manner. Additionally, the highly affinitive and selective viral
p19 protein does not bind ssRNA, tRNA or rRNA. This
eliminates the possibility of false results from mismatched
binding.155 Detection of 250 molecules in 4 minutes was suffi-
cient to determine miRNA concentration with 93%
condence.154
A different approach from using viral proteins for probe-
specic miRNAs detection is to employ an engineered-probe
with a programmable sequence to differentiate single nucleo-
tide differences in miRNA family members.150 The Wang et al.
proposed a system that enabled sensitive, selective, and direct
quantications of cancer-associated miRNAs in the blood. In
this study, the group constructed a robust protein nanopore-
based sensor that utilized an oligonucleotide probe (P155) to
detect aberrant expression of miRNA-155 and let-7a-2 from lung
cancer patients.150 The generated signature electrical signals
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3 * Label- and tether-free. Does not
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10, 74–76,





3 3 Methyl specic
labelers
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false-positive results and allow
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Real-time detection for all four
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of methylation on CpGs. Thus, it is
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and map the methylation prole
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provided a direct and label-free detection of the target miRNA in
a uctuating background, such as plasma RNA extract.150 Probe
(P155) has a programmable sequence and can be optimized to
achieve high sensitivity and selectivity. Additionally, using
chemical modications, distinct probes can further be engi-
neered with specic barcodes, allowing multiple miRNAs to be
simultaneously detected. Furthermore, with the development of
miRNA markers, manipulatable miRNA prole detection NP
arrays can be constructed for a noninvasive screening and early
diagnosis of cancer.150
Comparing to qRT-PCR assays, microarrays, colorimetry,
bioluminescence, and other current methods,146–149 NP arrays is
a simpler, faster methods to detect miRNAs in cancer patients.
This approach lacks all the complications that conventional
methods have, such as DNA amplication errors, unavailable
internal controls, and cross-hybridization. Early detection is
one of the most crucial contributors to a higher survival rate,
especially lung cancer patients (Fig. 6).151
6. Summary and conclusions
In this paper, we have concisely reviewed the main genetic and
epigenetic causal factors of cancer, as well as summarized how
NPs have been used in the research of each factor. Thanks to
several unique features of this emerging technology, the NP-
based analysis offers four main benets: rstly, NP analysis
offers long reads of genomic DNA (>10 kB). Therefore, linkages
between modied cytosines may be revealed that are biologi-
cally signicant and otherwise difficult to discern. For example,
it was shown that histone–DNA interaction is not affected by
methylation of DNA. Also, for the rst time, differences between
caC, fC, and hmC from mC were successfully distinguished.
Secondly, the genomic DNA is read directly as it transports
through the NP. Thus, errors (false-positive results) caused by
copying do not occur. Thirdly, with biological NP membranes,
the study of biomolecules' folding-unfolding kinetics and
mechanisms are possible to accomplish. Furthermore, the DNA
fragment can be retained in NP indenitely, allowing rereads of
a captured DNA fragment.123 Lastly, many conventional
methods are still impractical for clinical testing, because these
methods require highly trained experts, intensive labor, a high
capital cost, and a large footprint. With NP technology, there are
no such requirements, offering more exibility and practicality
for research labs and clinics (Table 1).
Although the concepts of NP analysis in early cancer detec-
tion are exceptionally promising, several key technological
challenges must be addressed before this method can be
implemented in clinical uses. First and foremost, the biggest
drawback of NP-based methods is high mismatch and error
rates. Because the NP membrane thickness, especially biolog-
ical ones, is relatively large comparing to a nucleotide, NP
sensitivity is still low at the single-nucleotide level. Further-
more, even though different DNA conformations and foldings
yield distinguishing characteristic current blockades, informa-
tion about the molecular structure cannot be determined by NP
membrane alone. In order to conrm the exact structure that
causes a signature blockades in NP, researchers need the aid of
other equipment, such as circular dichroism (CD), FRET, FISH,
among many others. This limits the use of NP membranes as an
independent, stand-alone tool for molecular studies in general,
and early cancer detection, specically. Moreover, since one
single biological molecule can quickly adopt multiple, complex
conformations under different environments, many research
groups choose to use short/simplied sequences in their NP
studies. Hence, the complexity of cancer cells has not yet been
demonstrated and/or fully investigated with NP membranes.
With this review paper, we hope to give our readers an
overview of the essential genetic and epigenetic modications
in cancerous tissue and the progression of cancer cells. With the
complexity of the human body and more specically cancer
tissues, many of the mechanisms for cancer proliferation
remain unknown. NP-based membranes have shown their
ability to detect various biomolecules chemical and structural
modications, as well as genetic and epigenetic modications.
Thus, NP technology could be the one simple solution replacing
many costly, labor-intensive conventional cancer screening
methods. With the complexity of the eld, there is growing
opportunity for more signicant research to be conducted in
the next few decades.
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S. B. Baylin, Proc. Natl. Acad. Sci. U. S. A., 1996, 93, 9821–9826.
104 C. A. Eads, K. D. Danenberg, K. Kawakami, L. B. Saltz,
C. Blake, D. Shibata, P. V. Danenberg and P. W. Laird,
Nucleic Acids Res., 2000, 28, e32.
105 M. F. Fraga and M. Esteller, BioTechniques, 2002, 33, 632–
649.
106 M. Weber, J. J. Davies, D. Wittig, E. J. Oakeley, M. Haase,
W. L. Lam and D. Schuebeler, Nat. Genet., 2005, 37, 853–
862.
107 I. Keshet, Y. Schlesinger, S. Farkash, E. Rand, M. Hecht,
E. Segal, E. Pikarski, R. A. Young, A. Niveleau and
H. Cedar, Nat. Genet., 2006, 38, 149–153.
108 B. Khulan, R. F. Thompson, K. Ye, M. J. Fazzari, M. Suzuki,
E. Stasiek, M. E. Figueroa, J. L. Glass, Q. Chen and
C. Montagna, Genome Res., 2006, 16, 1046–1055.
109 J. Shim, J. A. Rivera and R. Bashir, Nanoscale, 2013, 5,
10887–10893.
110 M. Tahiliani, K. P. Koh, Y. Shen, W. A. Pastor,
H. Bandukwala, Y. Brudno, S. Agarwal, L. M. Iyer,
D. R. Liu and L. Aravind, Science, 2009, 324, 930–935.
111 S. Ito, A. C. D'Alessio, O. V. Taranova, K. Hong, L. C. Sowers
and Y. Zhang, Nature, 2010, 466, 1129–1133.
112 H. Zhang, X. Zhang, E. Clark, M. Mulcahey, S. Huang and
Y. G. Shi, Cell Res., 2010, 20, 1390–1393.


























































































113 H. Wu and Y. Zhang, Genes Dev., 2011, 25, 2436–2452.
114 A. Szwagierczak, S. Bultmann, C. S. Schmidt, F. Spada and
H. Leonhardt, Nucleic Acids Res., 2010, 38, e181.
115 M. Wossidlo, T. Nakamura, K. Lepikhov, C. J. Marques,
V. Zakhartchenko, M. Boiani, J. Arand, T. Nakano,
W. Reik and J. Walter, Nat. Commun., 2011, 2, 241.
116 M. J. Booth, M. R. Branco, G. Ficz, D. Oxley, F. Krueger,
W. Reik and S. Balasubramanian, Science, 2012, 336, 934–
937.
117 T. S. Shankar and L. Willems, Vasc. Pharmacol., 2014, 60,
57–66.
118 Y. Fu and C. He, Curr. Opin. Chem. Biol., 2012, 16, 516–524.
119 C. G. Lian, Y. Xu, C. Ceol, F. Wu, A. Larson, K. Dresser,
W. Xu, L. Tan, Y. Hu and Q. Zhan, Cell, 2012, 150, 1135–
1146.
120 M. Yu, G. C. Hon, K. E. Szulwach, C.-X. Song, L. Zhang,
A. Kim, X. Li, Q. Dai, Y. Shen and B. Park, Cell, 2012, 149,
1368–1380.
121 M. Wanunu, D. Cohen-Karni, R. R. Johnson, L. Fields,
J. Benner, N. Peterman, Y. Zheng, M. L. Klein and
M. Drndic, J. Am. Chem. Soc., 2011, 133, 486–492.
122 A. H. Laszlo, I. M. Derrington, H. Brinkerhoff,
K. W. Langford, I. C. Nova, J. M. Samson, J. J. Bartlett,
M. Pavlenok and J. H. Gundlach, Proc. Natl. Acad. Sci. U.
S. A., 2013, 110, 18904–18909.
123 Z. L. Wescoe, J. Schreiber and M. Akeson, J. Am. Chem. Soc.,
2014, 136, 16582–16587.
124 C. T. Nguyen, F. A. Gonzales and P. A. Jones, Nucleic Acids
Res., 2001, 29, 4598–4606.
125 J. A. Fahrner, S. Eguchi, J. G. Herman and S. B. Baylin,
Cancer Res., 2002, 62, 7213–7218.
126 E. Ballestar, M. F. Paz, L. Valle, S. Wei, M. F. Fraga,
J. Espada, J. C. Cigudosa, T. H. M. Huang and M. Esteller,
EMBO J., 2003, 22, 6335–6345.
127 M. F. Fraga, E. Ballestar, A. Villar-Garea, M. Boix-Chornet,
J. Espada, G. Schotta, T. Bonaldi, C. Haydon, S. Ropero
and K. Petrie, Nat. Genet., 2005, 37, 391–400.
128 Y. Wang, W. Fischle, W. Cheung, S. Jacobs,
S. Khorasanizadeh and C. D. Allis, Novartis Found. Symp.,
2004, 259, 3–17.
129 J. Dobosy and E. Selker, Cell. Mol. Life Sci., 2001, 58, 721–
727.
130 P. A. Wade, BioEssays, 2001, 23, 1131–1137.
131 D. B. Seligson, S. Horvath, T. Shi, H. Yu, S. Tze,
M. Grunstein and S. K. Kurdistani, Nature, 2005, 435,
1262–1266.
132 D. Wu, A. Ingram, J. H. Lahti, B. Mazza, J. Grenet,
A. Kapoor, L. Liu, V. J. Kidd and D. Tang, J. Biol. Chem.,
2002, 277, 12001–12008.
133 C. Gabler, N. Blank, T. Hieronymus, M. Schiller, J. Berden,
J. Kalden and H. Lorenz, Ann. Rheum. Dis., 2004, 63, 1135–
1144.
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